SGEN stock forecast
Our latest prediction for Seattle Genetics, Inc.'s stock price was made on the Aug. 3, 2020 when the stock price was at 169.04$.
In the short term (2weeks), SGEN's stock price should underperform the market by -1.00%. During that period the price should oscillate between -7.58% and +6.27%.
In the medium term (3months), SGEN's stock price should underperform the market by -4.32%. During that period the price should oscillate between -26.49% and +15.89%.Get email alerts
Create a solid portfolio with SGEN
About Seattle Genetics, Inc.
Seattle Genetics, Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its products include Adcetris and Padcev. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.
At the moment the company generates 1016M USD in revenues.
On its last earning announcement, the company reported a loss of -1.49$ per share.
The book value per share is 8.69$
Three months stock forecastAug. 3, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|